Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 741-743

  Herr, Ingrid ^a   Groth, Ariane ^b   Salnikov, Alexei V ^a   Büchler, Markus W ^a   Moldenhauer, Gerhard ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Bispecific antibodies; Cancer stem cells; Gene immunotherapy; Granzyme perforin

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL DEATH; CYTOLYSIS; DRUG EFFICACY; EFFECTOR CELL; EX VIVO STUDY; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 84886944051     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19532     Document Type: Article

References (9)

1. McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelialspecific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 2001; 61:4105-11; PMID:11358833
2. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-21; PMID:20473913; http://dx.doi.org/10.1002/ijc.25423
3. Salnikov AV, Groth A, Apel A, Kallifatidis G, Beckermann BM, Khamidjanov A, et al. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J Cell Mol Med 2009; 13(9B):4023-33; PMID:20196789; http://dx.doi.org/10.1111/j.1582-4934.2009.00723.x
4. Marmé A, Strauss G, Bastert G, Grischke EM, Moldenhauer G. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 2002; 101:183-9; PMID:12209996; http://dx.doi.org/10.1002/ijc.10562
5. Groth A, Salnikov AV, Ottinger S, Gladkich J, Kallifatidis G, Salnikova O, et al. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clin Cancer Res 2012; In press; PMID:22228630; http://dx.doi.org/10. 1158/1078-0432.CCR-11-2767
6. Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells. Clin Cancer Res 2012; 18:465-74; PMID:22096026
7. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25:1390-5; PMID: 17416859; http://dx.doi.org/10.1200/JCO.2006.08.8898
8. Hoffmann SC, Wabnitz GH, Samstag Y, Moldenhauer G, Ludwig T. Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy. Int J Cancer 2011; 128:2096-104; PMID:20635391; http://dx.doi.org/10.1002/ijc.25556
9. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461:282-6; PMID: 19741708; http://dx.doi.org/10.1038/nature0829